Failure to Monitor Blood Glucose for Resident on Insulin Glargine
Summary
The deficiency involves the facility’s failure to monitor blood glucose levels for a resident receiving Insulin Glargine (Lantus), contrary to professional standards of practice and the resident’s care plan. The manufacturer’s prescribing information for Insulin Glargine specifies that dosing should be individualized and adjusted based on metabolic needs, blood glucose monitoring results, and glycemic control goals, and notes that the medication is contraindicated during episodes of hypoglycemia. Despite these requirements, the resident was started on Insulin Glargine 10 units subcutaneously at bedtime for regulation of blood glucose, without any corresponding physician’s orders for blood sugar monitoring or accu-checks. The resident had a medical history that included Type 2 Diabetes Mellitus and had recently been hospitalized with diagnoses including Type 2 Diabetes, sepsis, and chronic kidney disease. Hospital records from the prior admission documented point-of-care glucose readings, including a low value of 60 mg/dl, followed by readings of 90 mg/dl and 109 mg/dl on the day of discharge. Upon admission to the facility, the resident’s physician orders and MAR reflected the initiation of Insulin Glargine therapy, but there was no documented baseline blood sugar at admission and no orders for ongoing blood glucose monitoring, despite the resident’s diabetic status and recent low blood sugar reading in the hospital. The resident’s care plan for diabetes stated that the resident was on a carbohydrate-controlled diet and included a goal of maintaining blood sugars within the physician’s acceptable range, with interventions to administer diabetes medications as ordered and to monitor for side effects and effectiveness. However, the clinical record contained no documented evidence that blood sugar levels were being monitored. On one occasion, a CNA reported that the resident had a pool of saliva at the corner of the mouth, prompting staff to check vital signs and blood sugar, which was found to be 54 mg/dl. Glucagon was administered, EMS was called, and the resident was transferred to the hospital, where the resident was admitted with hypoglycemia, sepsis, and for wound evaluation. The DON and facility physician later confirmed that there had been no orders for fingerstick blood sugar monitoring, that such monitoring should have been in place, and that the lack of monitoring was an oversight.
Penalty
Resources
Below are regulatory guidelines relevant to this citation:
Trusted data from CMS and state health departments
Every citation, penalty and Plan of Correction is sourced from public CMS records (latest release July 29, 2026) and official state health department websites — never guesswork.
In your survey window? See what surveyors are citing.
The Survey-Prep Report maps your facility's risk from 12 months of CMS and state citation data — what's being cited around you and what to check first. $129 one-time.